ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zafgen, Inc.
• Treatments: CKD732

Criteria

Inclusion Criteria:

• Obese but otherwise healthy females

• Non-childbearing potential (surgically sterile, post-menopausal, or receiving implanted or injectable contraceptive for at least 3 months)

• BMI ≥ 30 and ≤ 45 kg/m2

• Stable body weight during the past 2 months

Exclusion Criteria:

• Use of weight loss agents in the past month

• History of eating disorder

• History of type 1 or type 2 diabetes mellitus

• Current smokers